18889881171
Kalkine 0
countryflagUS
L

AAPL 189.1 -6.9344% MSFT 361.17 -3.2001% NVDA 93.9716 -7.69% GOOGL 147.225 -2.3189% GOOG 149.2 -2.2473% AMZN 173.59 -2.7016% META 506.8 -4.6687% AVGO 148.55 -3.5452% LLY 738.02 -6.472% TSLA 239.865 -10.257% TSM 146.085 -7.1769% V 316.3 -6.8034% JPM 211.125 -7.1121% UNH 529.505 -2.0234% NVO 62.66 -6.617% WMT 83.2 -4.6528% LVMUY 114.68 -4.497% XOM 105.06 -6.5552% LVMHF 575.0 -4.485% MA 496.24 -6.4669%
AAPL 189.1 -6.9344% MSFT 361.17 -3.2001% NVDA 93.9716 -7.69% GOOGL 147.225 -2.3189% GOOG 149.2 -2.2473% AMZN 173.59 -2.7016% META 506.8 -4.6687% AVGO 148.55 -3.5452% LLY 738.02 -6.472% TSLA 239.865 -10.257% TSM 146.085 -7.1769% V 316.3 -6.8034% JPM 211.125 -7.1121% UNH 529.505 -2.0234% NVO 62.66 -6.617% WMT 83.2 -4.6528% LVMUY 114.68 -4.497% XOM 105.06 -6.5552% LVMHF 575.0 -4.485% MA 496.24 -6.4669%

Cabaletta Bio Inc

Healthcare US CABA

1.12USD
-0.07(5.88%)

Last update at 2025-04-04T18:56:00Z

Day Range

1.081.18
LowHigh

52 Week Range

9.5526.35
LowHigh

Fundamentals

  • Previous Close 1.19
  • Market Cap515.11M
  • Volume977426
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-84.28100M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.67

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

2018-12-312019-12-312020-12-312021-12-312022-12-31-50M-45M-40M-35M-30M-25M-20M-15M-10M-5M0M
Total Revenue
Net Income

Balancesheet

2019-12-312020-12-312021-12-312022-12-312023-12-310M20M40M60M80M100M120M140M160M180M200M220M240M
Total Assets
Total Liabilities

Change in Cash

2018-12-312019-12-312020-12-312021-12-312022-12-31-40M-20M0M20M40M60M80M100M

Total Operating Cash

2018-12-312019-12-312020-12-312021-12-312022-12-31-50M-45M-40M-35M-30M-25M-20M-15M-10M-5M0M

Dividends Paid

2018-12-312019-12-312020-12-312021-12-312022-12-31-10M-9M-8M-7M-6M-5M-4M-3M-2M-1M0M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -52.97500M -46.28900M -33.33900M -16.94300M -12.20200M
Minority interest - - - - -
Net income -51.81100M -45.53200M -32.49100M -15.09900M -12.20200M
Selling general administrative 14.84M 13.82M 12.46M 7.01M 1.73M
Selling and marketing expenses - - - - -
Gross profit - - 0.00000M - -
Reconciled depreciation 1.18M 0.73M 0.35M 0.10M -
Ebit -55.31700M -47.04600M -34.18700M -18.78700M -0.18400M
Ebitda -54.13900M -46.31300M -33.83300M -18.68300M -6.19300M
Depreciation and amortization 1.18M 0.73M 0.35M 0.10M -6.00900M
Non operating income net other 1.16M - 0.49M - -
Operating income -54.13900M -46.31300M -33.83300M -18.68300M -6.19300M
Other operating expenses 54.14M 46.31M 33.83M 18.68M 6.19M
Interest expense -1.17800M 0.73M 0.49M 0.00000M 0.00000M
Tax provision - - - - -
Interest income 1.16M 0.02M 0.49M 1.74M 0.23M
Net interest income 1.16M 0.02M 0.49M 1.74M 0.23M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.16400M -0.75700M -0.84800M -1.84400M -0.23500M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 54.14M 46.31M 33.83M 18.68M 6.19M
Cost of revenue - - - - -
Total other income expense net 1.16M 0.02M 0.49M 1.74M -6.24400M
Discontinued operations - - - - -
Net income from continuing ops -52.97500M -46.28900M -33.33900M -16.94300M -12.20200M
Net income applicable to common shares -52.97500M -46.28900M -33.33900M -22.26900M -12.20200M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 253.65M 116.97M 126.34M 114.72M 141.47M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 3.24M 2.29M 2.32M 4.87M 4.35M
Total liab 17.45M 12.45M 8.38M 5.18M 3.15M
Total stockholder equity 236.20M 104.52M 117.96M 109.54M 138.32M
Deferred long term liab - - - - -
Other current liab 7.89M 4.85M 6.05M 3.94M 2.23M
Common stock - - - - -
Capital stock 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Retained earnings -233.23700M -165.56200M -112.58700M -66.29800M -32.95900M
Other liab - - - - -
Good will - - - - -
Other assets 0.00000M 0.56M 0.36M 0.00030M 0.10M
Cash 193.24M 81.61M 122.22M 101.43M 136.20M
Cash and equivalents - - - - -
Total current liabilities 15.99M 9.49M 8.38M 5.18M 3.15M
Current deferred revenue - - - - -
Net debt -188.22000M -76.46900M -122.22200M -101.42900M -136.20400M
Short term debt 3.56M 2.18M - - -
Short long term debt - - - - -
Short long term debt total 5.02M 5.14M - - -
Other stockholder equity 469.40M 270.13M 230.54M 175.84M 29.81M
Property plant equipment - 2.58M 1.44M 0.89M 0.81M
Total current assets 244.49M 108.83M 124.54M 113.53M 140.55M
Long term investments - - - - -
Net tangible assets - 104.52M 116.61M 109.54M 138.32M
Short term investments 48.01M 24.94M - 7.23M -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 4.55M 2.46M 2.33M 1.24M 0.92M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.04M -0.04700M - 0.00600M -0.10400M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - -165.56200M - -66.29800M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.71M 0.56M 0.36M 0.30M 0.10M
Deferred long term asset charges - - - - -
Non current assets total 9.16M 8.13M 1.79M 1.19M 0.92M
Capital lease obligations 5.02M 5.14M - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -24.76400M 7.17M -7.98100M -7.34600M -7.34600M
Change to liabilities -1.21300M 0.97M 0.56M 0.25M 0.23M
Total cashflows from investing activities -27.21700M 6.00M -7.98100M -0.69300M -0.69300M
Net borrowings - - - - 12.54M
Total cash from financing activities 32.98M 48.90M -0.02400M 119.92M 37.68M
Change to operating activities -4.27100M 4.61M 1.15M -1.75200M -0.69800M
Net income -52.97500M -46.28900M -33.33900M -16.94300M -12.20200M
Change in cash -40.61500M 20.79M -34.77500M 103.19M 33.02M
Begin period cash flow 122.22M 101.43M 136.20M 33.02M 0.00100M
End period cash flow 81.61M 122.22M 101.43M 136.20M 33.02M
Total cash from operating activities -46.38000M -34.10900M -26.77000M -16.04500M -4.66100M
Issuance of capital stock 32.85M 48.32M 0.03M 121.21M 25.31M
Depreciation 1.18M 0.73M 0.35M 0.10M 0.10M
Other cashflows from investing activities - - - - -
Dividends paid - - - -10.09000M -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 0.08M 0.07M -0.19200M -1.29300M -0.16900M
Other cashflows from financing activities 0.05M 0.58M 0.14M 70.19M 37.85M
Change to netincome 6.90M 5.87M 4.51M 2.30M 8.01M
Capital expenditures 2.45M 1.17M 0.64M 0.69M 0.69M
Change receivables - - - - -
Cash flows other operating -0.72900M - -0.72200M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -40.61500M - -34.77500M - -
Change in working capital -4.29900M 5.58M 1.71M -1.50600M -0.46400M
Stock based compensation 6.90M 5.80M 4.39M 2.30M 0.61M
Other non cash items 2.82M 0.06M 0.12M -105.86000M 7.40M
Free cash flow -48.83300M -35.27500M -27.40500M -16.73800M -4.66100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
CABA
Cabaletta Bio Inc		 -0.07 5.88% 1.12 - - - 3.48 -8.0024
NVO
Novo Nordisk A/S		 -4.44 6.62% 62.66 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -3.842 5.72% 63.30 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -5.74 1.19% 478.27 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -27.19 4.45% 583.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Cabaletta Bio Inc

2929 Arch Street, Philadelphia, PA, United States, 19104

Key Executives

Name Title Year Born
Dr. Steven A. Nichtberger M.D. Co-Founder, Chairman, CEO & Pres 1961
Dr. Gwendolyn K. Binder Ph.D. Pres of Science & Technology 1975
Dr. David J. Chang FACR, M.D., M.P.H. Chief Medical Officer 1963
Dr. Michael C. Milone M.D., Ph.D. Co-Founder & Co-Chair of Scientific Advisory Board NA
Dr. Aimee Payne M.D., Ph.D. Co-Founder & Co-Chair of Scientific Advisory Board NA
Mr. Anup Marda M.B.A. Chief Financial Officer 1977
Dr. Samik Basu M.D. Chief Scientific Officer NA
Mr. Michael Gerard J.D. Gen. Counsel & Sec. 1980
Ms. Heather Harte-Hall M.Sc. Chief Compliance Officer NA
Ms. Martha O'Connor Chief HR Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.